TY - JOUR
T1 - Fungal DNA-barcoding on a chip
T2 - Magnetoresistive biosensors for yeast infection diagnosis
AU - Zolotareva, Maria
AU - Cascalheira, Francisco
AU - Afonso, Rúben
AU - Corado, Maria
AU - Martins, Ana
AU - Caneiras, Cátia
AU - Bárbara, Cristina
AU - Teixeira, Miguel Cacho
AU - Caetano, Diogo Miguel
N1 - Publisher Copyright:
© 2025 The Author(s). VIEW published by Shanghai Fuji Technology Consulting Co., Ltd, authorized by China Professional Community of Experimental Medicine, National Association Health Industry Enterprise Management (CPCEM) and John Wiley & Sons Australia, Ltd.
PY - 2025/12
Y1 - 2025/12
N2 - The worldwide burden of fungal infection has been increasing due to the expansion of the endemic borders, the host range of certain mycosis, and the emergence of novel opportunistic, drug and multi-drug-resistant fungal pathogens. Many deaths can be attributed to slow, inaccurate, or absent diagnostic testing and a lack of timely administration of effective antifungal treatment. Panfungal PCR followed by sequence identification has the practical advantage of rapidly and accurately detecting slow-growing, unculturable and even rare, unexpected or novel pathogens. We have developed and tested a robust and flexible biosensing diagnostic strategy, consisting of panfungal rDNA amplification, DNA hybridization, and magnetic labeling on a portable microfluidic setup. We designed DNA-capture probes specific for Candida albicans, Candida auris, Nakaseomyces glabratus, and Cryptococcus neoformans, and evaluated them for diagnostic sensitivity and specificity assessment, first in silico against a dataset of 58 pathogenic species (1239 DNA sequences), and then in vitro against the four species and 30 unsequenced clinical isolates of N. glabratus. On-chip, our assay performed with 95% accuracy, 91% sensitivity, and 98% specificity under a limit of detection of 600 single-stranded amplified ITS DNA sequences. Our results demonstrate the diagnostic value of DNA-barcoding and magnetoresistive biosensing, emphasizing the revolutionizing potential of DNA-sequence-based technologies in clinical practice.
AB - The worldwide burden of fungal infection has been increasing due to the expansion of the endemic borders, the host range of certain mycosis, and the emergence of novel opportunistic, drug and multi-drug-resistant fungal pathogens. Many deaths can be attributed to slow, inaccurate, or absent diagnostic testing and a lack of timely administration of effective antifungal treatment. Panfungal PCR followed by sequence identification has the practical advantage of rapidly and accurately detecting slow-growing, unculturable and even rare, unexpected or novel pathogens. We have developed and tested a robust and flexible biosensing diagnostic strategy, consisting of panfungal rDNA amplification, DNA hybridization, and magnetic labeling on a portable microfluidic setup. We designed DNA-capture probes specific for Candida albicans, Candida auris, Nakaseomyces glabratus, and Cryptococcus neoformans, and evaluated them for diagnostic sensitivity and specificity assessment, first in silico against a dataset of 58 pathogenic species (1239 DNA sequences), and then in vitro against the four species and 30 unsequenced clinical isolates of N. glabratus. On-chip, our assay performed with 95% accuracy, 91% sensitivity, and 98% specificity under a limit of detection of 600 single-stranded amplified ITS DNA sequences. Our results demonstrate the diagnostic value of DNA-barcoding and magnetoresistive biosensing, emphasizing the revolutionizing potential of DNA-sequence-based technologies in clinical practice.
KW - DNA biosensors
KW - ITS probes
KW - fungal infection diagnosis
KW - hybridization probes
KW - magnetic DNA labeling
KW - molecular diagnostics
UR - https://www.scopus.com/pages/publications/105015420293
U2 - 10.1002/VIW.20250015
DO - 10.1002/VIW.20250015
M3 - Article
AN - SCOPUS:105015420293
SN - 2688-3988
VL - 6
JO - VIEW
JF - VIEW
IS - 6
M1 - 20250015
ER -